Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Debiopharm and Oncodesign Launch Strategic Collaboration for Radiopharmaceuticals
Details : Under the licensing agreement, Oncodesign will holds the rights of AbYlink technology aiming for drug discovery and preclinical services.
Product Name : Undisclosed
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Servier Collaborates in The Treatment of Pancreatic Cancer
Details : Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Servier
Deal Size : $363.3 million
Deal Type : Partnership
Oncodesign and Servier Reach a Key First Milestone
Details : The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $3.3 million
February 17, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Servier
Deal Size : $363.3 million
Deal Type : Partnership
Reset All
